Magenta Therapeutics, which is developing novel therapies to make stem cell transplants more effective, filed on Thursday with the SEC to raise up to $100 million in an initial public offering.
The Cambridge, MA-based company was founded in 2015 by Third Rock Ventures and Atlas Venture and plans to list on the Nasdaq under the symbol MGTA. J.P. Morgan, Goldman Sachs and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
